🎉 M&A multiples are live!
Check it out!

Harmony Biosciences Hldgs Valuation Multiples

Discover revenue and EBITDA valuation multiples for Harmony Biosciences Hldgs and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Harmony Biosciences Hldgs Overview

About Harmony Biosciences Hldgs

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.


Founded

2017

HQ

United States of America
Employees

268

Financials

LTM Revenue $751M

LTM EBITDA $253M

EV

$1.4B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Harmony Biosciences Hldgs Financials

Harmony Biosciences Hldgs has a last 12-month revenue of $751M and a last 12-month EBITDA of $253M.

In the most recent fiscal year, Harmony Biosciences Hldgs achieved revenue of $715M and an EBITDA of $233M.

Harmony Biosciences Hldgs expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Harmony Biosciences Hldgs valuation multiples based on analyst estimates

Harmony Biosciences Hldgs P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $582M $715M XXX XXX XXX
Gross Profit $354M $461M XXX XXX XXX
Gross Margin 61% 64% XXX XXX XXX
EBITDA $222M $233M XXX XXX XXX
EBITDA Margin 38% 33% XXX XXX XXX
Net Profit $181M $129M XXX XXX XXX
Net Margin 31% 18% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Harmony Biosciences Hldgs Stock Performance

As of April 15, 2025, Harmony Biosciences Hldgs's stock price is $30.

Harmony Biosciences Hldgs has current market cap of $1.7B, and EV of $1.4B.

See Harmony Biosciences Hldgs trading valuation data

Harmony Biosciences Hldgs Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.4B $1.7B XXX XXX XXX XXX $2.69

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Harmony Biosciences Hldgs Valuation Multiples

As of April 15, 2025, Harmony Biosciences Hldgs has market cap of $1.7B and EV of $1.4B.

Harmony Biosciences Hldgs's trades at 1.9x LTM EV/Revenue multiple, and 5.6x LTM EBITDA.

Analysts estimate Harmony Biosciences Hldgs's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Harmony Biosciences Hldgs and 10K+ public comps

Harmony Biosciences Hldgs Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.4B XXX XXX XXX
EV/Revenue 2.0x XXX XXX XXX
EV/EBITDA 6.0x XXX XXX XXX
P/E 11.6x XXX XXX XXX
P/E/Growth 0.4x XXX XXX XXX
EV/FCF 6.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Harmony Biosciences Hldgs Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Harmony Biosciences Hldgs Valuation Multiples

Harmony Biosciences Hldgs's NTM/LTM revenue growth is 18%

Harmony Biosciences Hldgs's revenue per employee for the last fiscal year averaged $2.7M, while opex per employee averaged $1.4M for the same period.

Over next 12 months, Harmony Biosciences Hldgs's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Harmony Biosciences Hldgs's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Harmony Biosciences Hldgs and other 10K+ public comps

Harmony Biosciences Hldgs Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 23% XXX XXX XXX XXX
EBITDA Margin 33% XXX XXX XXX XXX
EBITDA Growth 5% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 51% XXX XXX XXX XXX
Revenue per Employee $2.7M XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue 16% XXX XXX XXX XXX
G&A Expenses to Revenue 15% XXX XXX XXX XXX
R&D Expenses to Revenue 20% XXX XXX XXX XXX
Opex to Revenue 51% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Harmony Biosciences Hldgs Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Harmony Biosciences Hldgs M&A and Investment Activity

Harmony Biosciences Hldgs acquired  XXX companies to date.

Last acquisition by Harmony Biosciences Hldgs was  XXXXXXXX, XXXXX XXXXX XXXXXX . Harmony Biosciences Hldgs acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Harmony Biosciences Hldgs

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Harmony Biosciences Hldgs

When was Harmony Biosciences Hldgs founded? Harmony Biosciences Hldgs was founded in 2017.
Where is Harmony Biosciences Hldgs headquartered? Harmony Biosciences Hldgs is headquartered in United States of America.
How many employees does Harmony Biosciences Hldgs have? As of today, Harmony Biosciences Hldgs has 268 employees.
Who is the CEO of Harmony Biosciences Hldgs? Harmony Biosciences Hldgs's CEO is Dr. Jeffrey M. Dayno, M.D..
Is Harmony Biosciences Hldgs publicy listed? Yes, Harmony Biosciences Hldgs is a public company listed on NAS.
What is the stock symbol of Harmony Biosciences Hldgs? Harmony Biosciences Hldgs trades under HRMY ticker.
When did Harmony Biosciences Hldgs go public? Harmony Biosciences Hldgs went public in 2020.
Who are competitors of Harmony Biosciences Hldgs? Similar companies to Harmony Biosciences Hldgs include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Harmony Biosciences Hldgs? Harmony Biosciences Hldgs's current market cap is $1.7B
What is the current revenue of Harmony Biosciences Hldgs? Harmony Biosciences Hldgs's last 12-month revenue is $751M.
What is the current EBITDA of Harmony Biosciences Hldgs? Harmony Biosciences Hldgs's last 12-month EBITDA is $253M.
What is the current EV/Revenue multiple of Harmony Biosciences Hldgs? Current revenue multiple of Harmony Biosciences Hldgs is 1.9x.
What is the current EV/EBITDA multiple of Harmony Biosciences Hldgs? Current EBITDA multiple of Harmony Biosciences Hldgs is 5.6x.
What is the current revenue growth of Harmony Biosciences Hldgs? Harmony Biosciences Hldgs revenue growth between 2023 and 2024 was 23%.
Is Harmony Biosciences Hldgs profitable? Yes, Harmony Biosciences Hldgs is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.